Precision Transplant Medicine: Biomarkers to the Rescue

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2017 Oct 11

PMID 28993504

Citations 36

Authors

Maarten Naesens

Dany Anglicheau

Affiliations

Soon will be listed here.

Abstract

The concept that individuals with the same disease and a similar clinical presentation may have very different outcomes and need very different therapies is not novel. With the development of many innovative tools derived from the omics technologies, transplant medicine is slowly entering the era of precision medicine. Biomarkers are the cornerstone of precision medicine, which aims to integrate biomarkers with traditional clinical information and tailor medical care to achieve the best outcome for an individual patient. Here, we discuss the basic concepts of precision medicine and biomarkers, with a specific focus on progress in renal transplantation. We delineate the different types of biomarkers and provide a general assessment of the current applications and shortcomings of previously proposed biomarkers. We also outline the potential of precision medicine in transplantation. Moving toward precision medicine in the field of transplantation will require transplant physicians to embrace the increased complexity and expanded decision algorithms and therapeutic options that are associated with improved disease nosology.

Citing Articles

Non-Invasive Biomarkers for Early Diagnosis of Kidney Allograft Dysfunction: Current and Future Applications in the Era of Precision Medicine.

Lazarou C, Moysidou E, Christodoulou M, Lioulios G, Sampani E, Dimitriadis C Medicina (Kaunas). 2025; 61(2).

PMID: 40005378 PMC: 11857372. DOI: 10.3390/medicina61020262.

Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.

Song Y, Wang Y, Wang W, Xie Y, Zhang J, Liu J J Transl Med. 2025; 23(1):147.

PMID: 39901268 PMC: 11792214. DOI: 10.1186/s12967-024-05964-4.

Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation.

Tinel C, Sauvaget V, Aouni L, Lamarthee B, Terzi F, Legendre C Sci Rep. 2024; 14(1):20357.

PMID: 39223175 PMC: 11369285. DOI: 10.1038/s41598-024-70390-x.

Cell-free DNA for the detection of kidney allograft rejection.

Aubert O, Ursule-Dufait C, Brousse R, Gueguen J, Racape M, Raynaud M Nat Med. 2024; 30(8):2320-2327.

PMID: 38824959 PMC: 11333280. DOI: 10.1038/s41591-024-03087-3.

Efficacy of Integrated Risk Score Using Omics-Based Biomarkers for the Prediction of Acute Rejection in Kidney Transplantation: A Randomized Prospective Pilot Study.

Lim J, Chung B, Lee S, Lee J, Kim Y, Han M Int J Mol Sci. 2024; 25(10).

PMID: 38791177 PMC: 11121528. DOI: 10.3390/ijms25105139.

References

Ho J, Rush D, Nickerson P . Urinary biomarkers of renal transplant outcome. Curr Opin Organ Transplant. 2015; 20(4):476-81. DOI: 10.1097/MOT.0000000000000208. View

Sis B, Mengel M, Haas M, Colvin R, Halloran P, Racusen L . Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010; 10(3):464-71. DOI: 10.1111/j.1600-6143.2009.02987.x. View

Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

Haas M, Sis B, Racusen L, Solez K, Glotz D, Colvin R . Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14(2):272-83. DOI: 10.1111/ajt.12590. View

Kuypers D . Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012; 8(7):390-402. DOI: 10.1038/nrneph.2012.64. View

van de Vrie M, Deegens J, Eikmans M, van der Vlag J, Hilbrands L . Urinary MicroRNA as Biomarker in Renal Transplantation. Am J Transplant. 2016; 17(5):1160-1166. PMC: 5434819. DOI: 10.1111/ajt.14082. View

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen J, Mooney N . Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369(13):1215-26. DOI: 10.1056/NEJMoa1302506. View

Dankers M, Witvliet M, Roelen D, de Lange P, Korfage N, Persijn G . The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation. 2004; 77(8):1236-9. DOI: 10.1097/01.tp.0000120385.03278.28. View

Schold J, Kaplan B . The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant. 2010; 10(5):1163-6. DOI: 10.1111/j.1600-6143.2010.03104.x. View

10.

Wiebe C, Nickerson P . Strategic Use of Epitope Matching to Improve Outcomes. Transplantation. 2016; 100(10):2048-52. DOI: 10.1097/TP.0000000000001284. View

11.

Sapir-Pichhadze R, Tinckam K, Quach K, Logan A, Laupacis A, John R . HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant. 2014; 15(1):137-48. DOI: 10.1111/ajt.12968. View

12.

Galichon P, Amrouche L, Hertig A, Brocheriou I, Rabant M, Xu-Dubois Y . Urinary mRNA for the Diagnosis of Renal Allograft Rejection: The Issue of Normalization. Am J Transplant. 2016; 16(10):3033-3040. DOI: 10.1111/ajt.13891. View

13.

Kotton C . Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010; 6(12):711-21. DOI: 10.1038/nrneph.2010.141. View

14.

Crespo E, Bestard O . Biomarkers to assess donor-reactive T-cell responses in kidney transplant patients. Clin Biochem. 2015; 49(4-5):329-37. DOI: 10.1016/j.clinbiochem.2015.08.010. View

15.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L . Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016; 374(4):333-43. DOI: 10.1056/NEJMoa1506027. View

16.

Fleming T, Powers J . Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012; 31(25):2973-84. PMC: 3551627. DOI: 10.1002/sim.5403. View

17.

Heidt S, San Segundo D, Shankar S, Mittal S, Muthusamy A, Friend P . Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation. 2011; 92(1):1-9. DOI: 10.1097/TP.0b013e318218e978. View

18.

Palacios C, Lieske J, Wadei H, Rule A, Fervenza F, Voskoboev N . Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013; 96(4):394-9. PMC: 4119827. DOI: 10.1097/TP.0b013e3182977ab1. View

19.

Tomas N, Hoxha E, Reinicke A, Fester L, Helmchen U, Gerth J . Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. 2016; 126(7):2519-32. PMC: 4922694. DOI: 10.1172/JCI85265. View

20.

Wiebe C, Pochinco D, Blydt-Hansen T, Ho J, Birk P, Karpinski M . Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013; 13(12):3114-22. DOI: 10.1111/ajt.12478. View